Monoclonal antibody | Bevacizumab | Interleukin-2 | Ipilimumab | Rituximab |
---|---|---|---|---|
Target | Vascular endothelial growth factor | Interleukin-2 receptor | Cytotoxic T lymphocyte antigen 4 | CD20 antigen |
Indications | Colorectal cancer, non-small cell lung cancer, and ovarian cancer | Melanoma and renal cell cancer | Melanoma and renal cell cancer | Hematologic B cell malignancies, nephrotic syndrome, and rheumatoid arthritis |
Side effects | Hypertension, proteinuria, arterial thromboembolic events, wound healing complications, bleeding diathesis, and gastrointestinal perforations | Fever and chills, diarrhea, diffuse erythroderma, hyperbilirubinemia, anemia, thrombocytopenia, eosinophilia, a capillary leak syndrome, and intestinal perforation | Dermatitis, endocrinopathies, particularly hypophysitis, uveitis, nephritis, inflammatory myopathies, hepatitis, colitis, and intestinal perforation | Fever and chills, mucocutaneous reactions, fatal infusion reactions, progressive multifocal leukoencephalopathy, and intestinal perforation |